Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

#TumorBoardTuesday Guru P. Sonpavde, MD Jon Anker, MD, PhD Uromigos Shilpa Gupta Mike Pishvaian Rafee Talukder Petros Grivas Matt Galsky Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition GrepMed LARVOL ASCO Fight Bladder Cancer BladderCancerCanada Jay B. Shah 6/7 #TumorBoardTuesday Case 🎀

Can we combine FGFRi w other tx?

-- NORSE & FORT-2 eval IO+ FGFRi
Hypothesis: FGFR ⬇️ TILs; inhibit FGFR 👉better chance of IO working

Local delivery also a 🔥🔥 topic!

#TumorBoardTuesday Guru P. Sonpavde, MD Jon Anker, MD, PhD Uromigos Shilpa Gupta Mike Pishvaian Rafee Talukder Petros Grivas Matt Galsky Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition GrepMed LARVOL ASCO Fight Bladder Cancer BladderCancerCanada Jay B. Shah 5/7 #TumorBoardTuesday Case 🎀

Cell free DNA expected to change how approach to mUC.

-- ctDNA + urinary cell-free DNA can be profiled
-- BISCAY clinic trial: significant role for liquid bx as tool to assign 🎯tx & monitor response-- more work coming!

#TumorBoardTuesday Guru P. Sonpavde, MD Jon Anker, MD, PhD Uromigos Shilpa Gupta Mike Pishvaian Rafee Talukder Petros Grivas Matt Galsky Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition GrepMed LARVOL ASCO Fight Bladder Cancer BladderCancerCanada Jay B. Shah 4.5/7 #TumorBoardTuesday

What about FGFR alterations in #BladderCancer ?

-- Assoc w luminal disease (tends to be less responsive to IO)
-- FGFR altered in 80% of NIMBC, 10-50% of MIBC

#TumorBoardTuesday Guru P. Sonpavde, MD Jon Anker, MD, PhD Uromigos Shilpa Gupta Mike Pishvaian Rafee Talukder Petros Grivas Matt Galsky Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition GrepMed LARVOL ASCO Fight Bladder Cancer BladderCancerCanada Jay B. Shah 4/7 #TumorBoardTuesday

With recent approval of EV-pembro as 1L tx for most w mUC, how do we 🤔 strategically about what comes next?

1L: EV-P vs gem/cis/nivo (pt factors, DM-II etc)
2L: Platinum
3L: 🎯tx (erda) if FGFR alteration #BladderCancer

1/7 Treatment of #urothelialcarcinoma #BladderCancer has changed significantly in 2023/2024! Join us 👇for our case wrap up: Guru P. Sonpavde, MD & Jon Anker, MD, PhD review key concepts-
-- Choosing 1L tx in mUC
-- Role of FGFR inhibitor (erda)
-- New approaches coming soon! #TumorBoardTuesday

Stop by our poster tomorrow at #AACR2024 to learn about neoantigen vaccination in urothelial cancer!

Immune checkpoint blockade has become a standard adjuvant treatment strategy in patients with muscle-invasive urothelial cancer after surgery. Should we build on this strategy with personalized neoantigen vaccination? Tom Powles Uromigos Bladder Cancer Advocacy Network #AACR2024

Late breaking research from Bhardwaj Lab, Matt Galsky and colleagues at #AACR2024 : Atezolizumab plus neoantigen vaccination for #bladdercancer
abstractsonline.com/pp8/#!/20272/p…
Poster, April 8, 9-12:30
Icahn School of Medicine at Mount Sinai

Coinciding with #EAU24 & hopefully timely given terrific data from Matt Galsky from #CheckMate274 & Tom Powles from #IMvigor011 - our attempt at adjuvant tx w #FGFR3 inhibitor #infigratinib . Huge international effort w co-PI Sia Daneshmand, M.D. & terrific SC incl Shilpa Gupta…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

Eagerly awaiting data from CM-274 at #EAU24 Adjuvant NIVOLUMAB showing improved OS in ITT and PD-L1 ≥1% urothelial cancers 🌟🌟🌟
#EAU24 #Oncology
Matt Galsky Tom Powles OncoAlert
Niklas Klümper Uromigos

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resource…

#OCENewsBurst

#TumorBoardTuesday 1/32 #TumorBoardTuesday #OncTwitter

Pt is coming in for follow up

68 yo 👨‍🦱 with UC, CKD3b

Recently diagnosed with de novo metastatic disease to LN, lungs

Routine NGS showed FGFR S249C

Jon Anker, MD, PhD #TumorBoardTuesday Johnathan Ebben MD, PhD Mike Pishvaian Brian Rini, MD Rana McKay Matt Galsky Petros Grivas Rafee Talukder Ali Khaki Tom Powles Shilpa Gupta Amanda Nizam, MD Neeraj Agarwal, MD, FASCO Andrew Armstrong Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad 𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜 Daniel Castellano Ciara Conduit Deborah Mukherji Elena Castro Edward Schaeffer Tamas Fazekas MD Jacob Berchuck Marisa Clifton Mohamed_omar Sarki Abdulkadir Scot Niglio MD Umang Swami Todd 〽️ Morgan, MD Choices for therapy of advanced #urothelialcarcinoma #bladdercancer are multiplying!

Jon Anker, MD, PhD #TumorBoardTuesday Brian Rini, MD Rana McKay Matt Galsky Petros Grivas Rafee Talukder Ali Khaki Tom Powles Shilpa Gupta Amanda Nizam, MD Neeraj Agarwal, MD, FASCO Andrew Armstrong Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad 𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜 Daniel Castellano Ciara Conduit Deborah Mukherji Elena Castro Edward Schaeffer Tamas Fazekas MD Jacob Berchuck Marisa Clifton Mohamed_omar Sarki Abdulkadir Scot Niglio MD Umang Swami Todd 〽️ Morgan, MD #TumorBoardTuesday

😉I am having a flashback to a prior Jon Anker, MD, PhD mUC discussion on #TumorBoardTuesday

x.com/TumorBoardTues…

#PreTest Q2⃣#TumorBoardTuesday Free #CME integrityce.com/TBT2024

🧐 Which kinase inhibitor combined w/ 1L cetrelimab has demonstrated an ORR of 54.5% in cisplatin-ineligible patients w/ FGFR altered or mutated🧬mUC❓

#PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT2024

B4⃣Guru P. Sonpavde, MD & Jon Anker, MD, PhD🗣️FGFR🎯💊for mUC, test your🧠with these 2❓

🤔What 2L Tx would you select for a 68yo♂️ w/stage 3B CKD and FGFR3 S249C🧬mutation➕mUC upon progression on enfortumab➕pembrolizumab❓

#TumorBoardTuesday
🏹We are taking aim at true targeted therapy this week🎯💊

📢Join us Tuesday, 04.02.2024 at 8PM ET as Guru P. Sonpavde, MD & Jon Anker, MD, PhD🗣️tailoring Tx in metastatic #urothelialcancer with FGFR🎯💊

RT and bring others into the discussion‼️